Amedisys (AMED) reported $594.78 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 4.1%. EPS of $1.25 for the same period compares to $1.03 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $594.79 million, representing no surprise. The company delivered an EPS surprise of +10.62%, with the consensus EPS estimate being $1.13.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Amedisys performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Service Revenue- Home health: $379.20 million versus $373.30 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.2% change.
• Net Service Revenue- High Acuity Care: $9.40 million versus $9.87 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +46.9% change.
• Net Service Revenue- Hospice: $206.20 million versus the three-analyst average estimate of $208.08 million. The reported number represents a year-over-year change of +2.6%.

View all Key Company Metrics for Amedisys here>>>

Shares of Amedisys have returned +0.1% over the past month versus the Zacks S&P 500 composite's -6.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amedisys, Inc. (AMED) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research